“Novo Nordisk heard loud and clear the impact to the 15,000 Australians living with diabetes who depended on FIASP, if FIASP was no longer available on the PBS. We are pleased that patients can continue accessing this treatment on the PBS,” said Cem Ozenc, corporate vice president and general manager of Novo Nordisk Oceania.
Patients win reprieve with Novo Nordisk listing a new form of insulin aspart
September 17, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 12 December
December 12, 2025 - - Podcast -
Medicines Australia gains a new voice with Vertex joining the association
December 11, 2025 - - Latest News -
BMS marks 70 years in Australia with renewed commitment to innovation and access
December 11, 2025 - - Latest News -
Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children
December 11, 2025 - - Latest News -
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech
